← all works
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian funderA Canadian agency funded it. The work may carry no Canadian affiliation at all.
No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet Respiratory Medicine
- Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Field
- Medicine
- Canadian institutions
- —
- Funders
- Roche ProductsCanadian Pulmonary Fibrosis FoundationGlaxoSmithKline
- Keywords
- MedicinePulmonary fibrosisPneumoniaInternal medicineIdiopathic pulmonary fibrosisPandemicIntensive care medicineFibrosisARDSDiffuse alveolar damageDiseaseCoronavirusCoronavirus disease 2019 (COVID-19)ImmunologyLungAcute respiratory distressInfectious disease (medical specialty)
- Has abstract in OpenAlex
- no